Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD0754 in metastatic prostate cancer
NCT06267729Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Mar 2024
- Primary completion
- Nov 2026
- Modality
- CAR-T Cells
- Countries
- 3
01
Overview
A Phase 2 trial of AZD0754 in Prostate Adenocarcinoma (PRAD), sponsored by AstraZeneca. Started Mar 2024; status: recruiting.
02
Drugs
AZD0754
03
Conditions
Prostate Adenocarcinoma (PRAD)
Beyond the preview
Go deeper on NCT06267729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06267729.